Navigation Links
BioSpecifics Technologies Corp. Reports Second Quarter 2013 Financial Results
Date:8/8/2013

LYNBROOK, N.Y., Aug. 8, 2013 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first-in-class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in the EU, today reported its financial results for the second quarter ended June 30, 2013 and provided a corporate update.

"We continue to make steady progress in the clinical development and commercial growth of XIAFLEX. We are anticipating a major landmark related to the U.S. Food and Drug Administration's decision on the potential approval of the supplemental Biologics License Application for Peyronie's disease. In addition we were pleased that our partner Auxilium announced a collaboration with Swedish Orphan Biovitrum to develop and market the drug in Eurasia and Africa, expanding its availability to many more patients in need," reflected Thomas L. Wegman, President of BioSpecifics. "We and Auxilium continue to develop XIAFLEX in other indications as well; we have completed enrollment in our Phase II human and canine lipoma trials and expect to announce top-line data from these trials in the second half of this year. Additionally, Auxilium is continuing the development of XIAFLEX in cellulite and frozen shoulder and we anticipate the initiation of new trials in those indications in 2013."

Second Quarter 2013 Financial Results BioSpecifics reported a net income of $1.0 million for the second quarter ended June 30, 2013, or $0.16 per basic share and $0.15 per diluted share, compared to a net income of $0.7 million, or $0.11 per basic share and $0.10 per diluted share for the same period in 2012.

Total revenue for the second quarter ended June 30, 2013 was $3.3 million, compared to $2.6 million for the same peri
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. BioSpecifics Technologies Corp. Announces Rescheduled First Quarter 2012 Financial Results Conference Call to May 10, 2012
2. BioSpecifics Technologies Corp. to Host Conference Call to Report Second Quarter 2012 Financial Results on August 9, 2012
3. BioSpecifics Technologies Corp. To Present at Stifel Nicolaus Weisel Healthcare Conference 2012
4. BioSpecifics Technologies Corp. to Present at Two Upcoming Investor Conferences in September
5. BioSpecifics Technologies Corp. to Host Conference Call to Report Third Quarter 2012 Financial Results on November 8, 2012
6. BioSpecifics Technologies Corp. to Webcast, Live, at RetailInvestorConferences.com on December 6th
7. BioSpecifics Technologies Corp. Announces Presentations at Upcoming Investor Conferences
8. BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2012 Financial Results on Tuesday, March 12, 2013
9. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2012 Financial Results
10. BioSpecifics Technologies Corp. to Host Conference Call to Report First Quarter 2013 Financial Results on Friday, May 10, 2013
11. BioSpecifics Technologies Corp. to Present at Jefferies 2013 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... CAMBRIDGE, Mass. , Jan. 15, 2014  Zafgen, ... the unmet needs of severely obese patients, today ... of beloranib, a selective inhibitor of methionine aminopeptidase ... a severe form of genetic obesity.  These results ...
(Date:1/14/2014)... HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the fourth quarter of 2013 will be approximately ... $208 million. "Our full-year revenue growth of ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North America,s ... of high-value chemistry, will hold the 30 th edition ... Convention Center from January 21-24. (Logo: ... from top pharmaceutical, fine chemical and specialty chemical companies will ...
Breaking Medicine Technology:Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... Scientists have identified the first genetic variant specifically ... sub-type accounting for around 10-15 per cent of ... study of the breast cancer sub-type, called invasive ... genetic causes of this particular kind of breast ... The research, published today (Thursday) in the journal ...
(Date:4/17/2014)... the most popular vaccine brands for children may not ... overlooking some cost factors when choosing vaccines, driving the ... according to a new study by University of Illinois ... be driven by numerous factors," says Sheldon H. Jacobson, ... computer science and of mathematics at the U. of ...
(Date:4/17/2014)... Biology and Medicine a multidisciplinary research team ... in the Institute of Genomic Biology (IGB) on ... describe their recent work on subcellular redox homeostasis. ... functions including energy metabolism, signaling, and transcriptional processes. ... cellular behavior, redox status has been recognized as ...
(Date:4/17/2014)... Two recent papers by a University of ... help scientists develop treatments or vaccines for Dengue ... and other disease-causing flaviviruses. , Jeffrey S. Kieft, ... at the School of Medicine and an early ... and colleagues recently published articles in the scholarly ...
(Date:4/17/2014)... Pediatrician-in-Chief Jon McCullers, MD, was recently invited to ... Nature Reviews Microbiology , one of the ... world-renowned infectious disease specialist, and chair of the ... Health Science Center, analyzed the epidemiology and microbiology ... pandemics, as well as more recent 2009 novel ...
Breaking Medicine News(10 mins):Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study recalculates costs of combination vaccines 2Health News:Live cell imaging reveals distinct alterations of subcellular glutathione potentials 2Health News:CU researchers discover target for treating dengue fever 2
... Bill Germanakos to Deliver NBGH Keynote Address, ... DGX ), the leading provider of diagnostic ... Business Group,on Health (NBGH), an association of more ... Best Employers for Healthy Lifestyles Gold Award to ...
... with seizures, SEATTLE, May 13 The Epilepsy ... in,Seattle, Spokane and Portland. The events will occur on ... Spokane at Riverfront Park. The following,day, Sunday, June 22, ... take place from 9:30 am-12:00 pm., "Everyone is ...
... 13 The Board of Directors of,MSA (NYSE: MSA ... per,share on common stock, payable June 10, 2008 to shareholders ... a dividend of 56-1/4 cents per share on,preferred stock, payable ... About MSA:, Established in 1914, MSA is a ...
... tobacco smoke respond particularly well to montelukast (Singulair) ... Research Center. Associate Professor of Pediatrics Nathan ... biomarkers that may help physicians predict even more ... These findings will help doctors know in advance ...
... Center,for Adoption announces a $10,000 grant from the Aetna ... during pregnancy., Kimberlee Walters-Sanders, an Aetna sales representative ... Head of Sales, will,present the award to Gladney staff ... Gladney,s campus, located at 6300 John Ryan Dr., Fort,Worth., ...
... Both Proposals -, LAKE FOREST, Ill., May 13 ... specialty pharmaceutical and medication,delivery company, today held its 2008 ... votes on two proposals and a brief,update on the ... to the success of our strategies of investing,for growth, ...
Cached Medicine News:Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 2Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 3Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 4Health News:Quest Diagnostics Is Named 'Best Employer For Healthy Lifestyles' 5Health News:Girls and children exposed to tobacco smoke benefit more from montelukast (singulair) 2Health News:Gladney Center for Adoption Receives Whole Health Grant from Aetna Foundation 2Health News:Hospira Highlights Strategic Initiatives at Its 2008 Annual Meeting of Shareholders 2
Bone Curette, 180 mm...
Endocrette Endocervical Curette is a stainless-steel curette with closed blade....
Townsend is a endocervical stainless-steel curette with round tapered tip....
Kevorkian Endocervical Curette is a stainless-steel curette with a basket. It is narrow tipped for sampling without dilation....
Medicine Products: